Abstract It has recently been reported that ␣B-crystallin, a low-molecular-weight heat shock protein, may be released from cells by mechanical stretch. We investigated a physiological role of ␣B-crystallin in platelet function. ␣B-crystallin inhibited platelet aggregation induced by thrombin or botrocetin in hamsters and humans. These platelets had specific binding sites for ␣B-crystallin. Moreover, ␣B-crystallin significantly reduced thrombin-induced Ca 2ϩ influx and phosphoinositide hydrolysis by phospholipase C in human platelets. Additionally, plasma levels of ␣B-crystallin were markedly elevated in cardiomyopathic hamsters. Levels of ␣B-crystallin in vessel walls after endothelial injury were markedly reduced. Therefore, our results suggest that ␣B-crystallin, which is discharged from vessel walls in response to endothelial injury, acts intercellularly as a regulator of platelet function.
INTRODUCTION
When cells are exposed to biological stresses such as heat, they produce heat shock proteins (HSPs) (Nover 1991; Nover and Scharf 1991) . HSPs are classified into highmolecular-weight HSPs and low-molecular-weight HSPs according to their apparent molecular sizes. High-molecular-weight HSPs such as Hsp90 and Hsp70 are well known to function as molecular chaperones implicated in protein folding, oligomerization, and translocation (Ellis and van der vies 1991; Gething and Sambrook 1992) . Low-molecular-weight HSPs such as Hsp27 and a ␣B-crystallin have significant similarities in terms of amino acid sequences (Hickey et al 1986; Ingolia et al 1982) . Although their function is less well understood than that of high-molecular-weight HSPs, it is recognized that lowmolecular-weight HSPs may act as chaperones as well (Benndorf et al 1994; Groenen et al 1994) .
␣B-crystallin is well known as a major structural protein of the vertebrate lens. It is presently recognized that ␣B-crystallin is present in various tissues and cells, including heart, brain, and skeletal muscle, where its cellular function is unknown (Kato et al 1991 Inaguma et al 1993) . It has recently been reported that the levels of ␣B-crystallin in trabecular meshwork cells are markedly decreased after 1 hour in response to mechanical stretch (Mitton et al 1997) . This finding suggested to us that ␣B-crystallin might be released from cells by stress such as mechanical stretch and act intercellularly. However, the exact mechanism of the decrease of ␣B-crystallin has not yet been clarified. In the present study, we investigated the behavior of ␣B-crystallin in injured vascular walls after endothelial mechanical stress in vivo using an experimental model of stenosis. Herein, we show that ␣B-crystallin binds to platelets and inhibits platelet aggregation.
MATERIALS AND METHODS

Materials
Thrombin and Bothorops jararaca (snake toxin) were obtained from Sigma Chemical (St Louis, MO, USA). Botrocetin was purified from Bothorops jararaca by the method of Fujimura (Fujimura et al 1991) . Fura 2-AM was obtained from Dojindo (Kumanoto, Japan).
Myo-[
3 H]inositol (81.3 Ci/mmol) was obtained from Amersham Japan (Tokyo, Japan). Other materials and chemicals were obtained from commercial sources.
Animals
Normal hamsters were purchased from SLC (Shizuoka, Japan). Cardiomyopathic hamsters (Bio 14.6 strain) and their wild type were obtained from Charles River Japan Inc (Tokyo, Japan). Male hamsters weighing 100 to 120 g were selected and fed a standard chow (RC4, Oriental Yeast Co, Ltd, Japan). All animal experiments were performed in according with institutional guidelines.
Immunoassay of ␣B-crystallin
The arteries were washed twice with 1 mL of phosphatebuffered saline (PBS) and frozen at Ϫ80ЊC for a few days before analysis. The frozen tissues from each group were homogenized and suspended in 0.3 mL of PBS, and each suspension was sonicated and centrifuged at 125 000 ϫ g for 20 minutes at 4ЊC. The supernatant was used for the specific immunoassay of ␣B-crystallin, as described previously (Kaida et al 1999) . In brief, we used an enzyme immunoassay system that employs polystyrene balls (3.2 mm in diameter, Immuno Chemicals, Okayama, Japan) carrying immobilized F(abЈ) 2 fragments of antibody and the same FabЈ fragments labeled with ␤-D-galactosidase from Escherichia coli. A polystyrene ball carrying antibodies was incubated with the purified standard for ␣B-crystallin or with an aliquot of the samples. This incubation was carried out at 30ЊC for 5 hours in a final volume of 0.5 mL of 10 mM sodium phosphate buffer, pH 7.0, containing 0.3 M NaCl, 0.5% hydrolyzed gelatin, 0.1% bovine serum albumin (BSA), 1 mM MgCl 2 , and 0.1% NaN 3 . After washing, each ball was incubated at 4ЊC overnight with 1.5 milliunits of galactosidase-labeled antibodies in a volume of 0.2 mL with 10 mM sodium phosphate buffer, pH 7.0, containing 0.l M NaCl, 1 mM MgCl 2 , 0.1% BSA, and 0.1% NaN 3 . The galactosidase activity bound to the ball was assayed using a fluorogenic substrate, 4-methylumbelliferyl-␤-D-galactoside.
Platelet aggregation in vitro
The effect of ␣B-crystallin on platelet aggregation was investigated in either platelet rich plasma (PRP) or washed platelets. Human blood was donated from young healthy male volunteers who had not taken any medications for the preceding 7 days. The blood was collected into 3.8% sodium citrate and centrifuged at 155 ϫ g for 12 minutes at room temperature to obtain PRP. Washed platelets for studies with thrombin were prepared as described previously (Matsuno et al 1997) . Platelets were counted and adjusted to 4 ϫ 10 8 cells/mL (final concentration). The concentration of 3.3 g/mL botrocetin or 0.3 U/mL thrombin was chosen to induce about 60% of aggregation. ␣B-crystallin was preincubated for 20 minutes with PRP or washed platelets. Platelet aggregation was followed in an aggregometer (Aggrecorder II; DA-3220, KyotodaiichiChemical, Kyoto, Japan) at 37ЊC with a stirring speed of 800 rpm. Aggregation is expressed as a percentage of the maximum light transmission obtained in the absence of ␣B-crystallin.
Pharmacokinetics of ␣B-crystallin and platelet aggregation ex vivo
Normal hamsters were anesthetized by intraperitoneal injection of pentobarbital (50 mg/kg), and ␣B-crystallin (30, 100, and 300 g/kg) was injected as a bolus (300 L) using a catheter via the left jugular vein. Blood samples (0.4 mL each) were taken at 5, l5, 30, and 60 minutes and 6 hours after the bolus injection for the measurement of plasma concentrations of ␣B-crystallin. In a separate experiment, ␣B-crystallin (30, 100, and 300 g/kg) was also injected as a bolus, and blood samples (0.4 mL each) were then taken by heart puncture 5 minutes after the bolus injection. Platelet aggregation induced by botrocetin (3.3 g/mL) using PRP was then investigated as described previously.
Radioiodination of ␣B-crystallin
125
I-labeled ␣B-crystallin was prepared by chloramine-Tmediated iodination (Hunter and Greenwood 1962) . ␣B-crystalline (20 g) was mixed with 1 mCi Na[ l25 I] in 100 L of 0.5 M sodium phosphate, pH 7.4, containing 0.5 M NaCl, then 100 L of l mg/mL chroramine T in 50 mM sodium phosphate, pH 7.4, containing 0.5 M NaCl were added to the mixture, which was incubated for 15 seconds at room temperature. The reaction was terminated by adding 100 L of 2.5 mg/mL sodium metabisulfate in 50 mM sodium phosphate, pH 7.4, containing 0.5 M NaCl, and the labeled protein was separated from free iodine by gel filtration on a Sephadex G-50 column equilibrated with Eagle's minimum essential medium, 25 mM Hepes/NaOH, pH 7.4, 0.5% BSA containing 5 mM Kl.
[ l25 I] ␣B-crystallin binding
The ␣B-crystallin binding assay was performed as previously described (Kodama et al 1992) . In brief, platelets (1 ϫ 10 8 ) were incubated in a binding assay medium for 10 minutes at 37ЊC, then mixed with 125 I-␣B-crystallin in the presence or absence of a 200-fold excess of unlabeled ␣B-crystallin in a final volume of 300 L of an assay buffer (10 mM HEPES, pH 7.4, 140 mM NaCl, 2.7 mM KCl, 12 mM NaHCO 3 , 0.4 mM NaH 2 PO 4 , 0.8 mM MgCl 2 , 5 mM glucose). After the incubation, the reaction mixture was layered onto 200 L of phthalate oil (dibutylphthalate/ bis[2-ethylhexyl]-phthalate [3:2]) and centrifuged at 10 000 ϫ g for 5 minutes. The sample was frozen and cut just above the cell pellet, and the cell-associated radioactivity was then determined.
Measurement of cytoplasmic free calcium concentration
Intracellular free calcium concentration was determined after loading human platelets with a fluorescent dye, fura 2-AM. PRP was incubated with 5 M fura 2-AM at 37ЊC for 30 minutes and then suspended at 2 ϫ 10 8 /mL in the assay buffer containing l mM CaCl 2 . The platelets were preincubated with ␣B-crystallin for 20 minutes and then stimulated by thrombin. Measurement of fura 2 was performed in a CAF-100 spectrofluorometer (JASCO, Japan). Fluorescence from fura 2 in platelets was excited with 2 excitation wavelengths of 340 and 380 nm, and the relative intensities of fluorescence were measured at 510 nm. Maximum fluorescence was achieved by lysing the platelets with 0.2% Triton X-100, and the minimum fluorescence was recorded in the presence of 2 mM EGTA. Cytoplasmic free calcium concentration was calculated by the Grynkiewicz equation (Grynkiewicz et al 1985) .
Formation of inositol phosphates
Platelets were labeled with myo-[ 3 H]inositol (100 Ci/ mL) for 3 hours. The labeled cells were preincubated with 10 mM LiCl for 10 minutes at 37ЊC in 1 mL of the assay buffer containing 1 mM CaCl 2 . The cells were pretreated with various doses of ␣B-crystallin for 20 minutes and then stimulated by thrombin at 37ЊC. The reaction was terminated by adding 1 mL of trichloroacetic acid. The acidic supernatant was treated with diethyl ether to remove the acid and neutralized with 0.1 N NaOH. The supernatant was applied to an anion exchange column containing 1 mL Dowex AG1-X8 (100-200 mesh formate, form; Bio-Rad Laboratories, Hercules, CA, USA). The radioactive inositol phosphates were eluted with 8 mL of 0.1 M formic acid containing 1 M ammonium formate as previously described (Berridge et al 1983; Kondo et al 1989) .
Detection of ␣B-crystallin in vivo
The experimental procedure used to induce endothelial injury in the hamster carotid artery was performed as previously described (Matsuno et al 1995) . The right common carotid artery of hamsters was subjected to mechanical stress by use of a catheter that denuded the endothelium and induced highly reproducible intimal proliferation of vascular smooth muscle cells over the entire length of the affected blood vessel. A 2FG catheter with a roughened tip was inserted through the external carotid artery and advanced into the thoratic aorta. The catheter was left in position for 30 seconds and rotated completely 3 times. By these means, endothelial cells were completely denuded, and several parts of the elastic lamina were ruptured. Platelet-rich thrombi were observed in injury areas immediately after the initiation of injury. Animals were divided into 6 groups. The injured carotid artery was removed 5, 30, and 60 minutes and 6 hours after the catheterization. Segments were homogenized in phosphate-buffer, and ␣B-crystallin levels were measured by the immunoassay.
The plasma levels of ␣B-crystallin in cardiomyopathic hamsters and their control hamsters were determined. Blood samples were taken via jugular vein at 6 weeks after they were born.
Determination of radioactivity
The radioactivity of 3 H samples was determined using a Beckman LS6500IC liquid scintillation spectrometer (Fullerton, CA, USA). The radioactivity of l25 I samples was determined using a Wallac 1480 WIZARD 3ЈЈ automatic gamma counter (Turk, Finland).
Other methods
Protein concentrations in soluble extracts were determined using a protein assay kit (Bio-Rad) with BSA as the standard protein. Rat ␣B-crystallin, which was used as the standard for the immunoassay, was purified from skeletal muscle (Kato et al 1991) .
Statistical analysis
The data were analyzed by ANOVA followed by Bonferroni method for multiple comparison between pairs, and a P Ͻ 0.05 was considered significant. All data are presented as the mean Ϯ SEM of triplicate determinations.
RESULTS
Effect of ␣B-crystallin on platelet aggregation in vitro
We first examined the effect of ␣B-crystallin on platelet aggregation induced by botrocetin or thrombin using human PRP. ␣B-crystallin significantly inhibited the platelet aggregation induced by botrocetin (Fig 1a) or thrombin (Fig 1b) . The inhibitory effect of ␣B-crystallin was dose dependent in the range between 0.1 and 30 g/mL. ␣B-crystallin (10 g/mL) almost completely suppressed the platelet aggregation induced by thrombin while reducing the botrocetin-induced platelet aggregation by about 40% . Fig 1. Effect of ␣B-crystallin on platelet aggregation in vitro using human platelets. The aggregation of platelets stimulated by botrocetin (3.3 g/mL) using PRP (a) or thrombin (0.3 U/mL) using washed platelets (b) was performed after preincubation for 20 minutes with ␣B-crystallin or vehicle. Each value represents the mean Ϯ SEM of triplicate determinations. * P Ͻ 0.05 vs the value of botrocetin alone, ** P Ͻ 0.05 vs the value of thrombin alone.
Fig 2.
The levels of plasma ␣B-crystallin after an intravenous injection (a) and effect of ␣B-crystallin on platelet aggregation ex vivo using normal hamster PRP (b). ␣B-crystallin was injected intravenously as a bolus at doses of 30 (circle), 100 (triangle), and 300 (square) g/ kg. The aggregation of platelets stimulated by botrocetin (3.3 g/mL) was performed after preincubation for 20 minutes with ␣B-crystallin. Each value represents the mean Ϯ SEM of triplicate determinations. * P Ͻ 0.05 versus the value of botrocetin without ␣B-crystallin. 
Plasma levels of ␣B-crystallin and effect of ␣B-crystallin on platelet aggregation ex vivo
Plasma levels of ␣B-crystallin after an intravenous bolus injection at doses of 30, 100, or 300 g/kg in hamsters are shown in Figure 2a . In addition, we investigated the effect of ␣B-crystallin on platelet aggregation ex vivo using hamsters. Platelet aggregation induced by botrocetin was inhibited by about 30% when ␣B-crystallin at a dose of 300 g/kg was administered intravenously (Fig 2b) .
Characterization of binding of 125 I-␣B-crystallin to platelets
125 I-␣B-crystallin binding to human platelets at 37ЊC reached equilibrium after 30 minutes. Thus, further bind- ing experiments were performed at 37ЊC for 30 minutes. Incubation of increasing concentrations of 125 I-␣B-crystallin with human platelets showed that the specific binding consisted of a saturable component (Fig 3) . The levels of nonspecific binding was linearly dependent on the concentration ␣B-crystallin and was about 30% of the total binding. Scatchard plot analysis of the binding data revealed that there were affinity sites for ␣B-crystallin on human platelets (Fig 3) . The Kd values of the affinity sites were 30 nM, and the average numbers were 3900 per cell.
Effect of ␣B-crystallin on thrombin-induced Ca
2؉ mobilization in human platelets
Thrombin induced a rapid and sharp increase in intracellular calcium concentration, followed by a slow and phasic increase, which then gradually decreased. ␣B-crystallin, which alone did not affect the basal levels of intracellular free Ca 2ϩ (data not shown), reduced the slow and phasic increase in cytoplasmic free Ca 2ϩ (Fig 4) . The effect of ␣B-crystallin was dose dependent in the range between 0.05 and 5 g/mL.
Effect of ␣B-crystallin on thrombin-induced inositol phosphates formation in human platelets
It has been shown that thrombin stimulates phosphoinositide hydrolysis by phospholipase C in platelets (Grand et al 1996) . Phosphoinositide hydrolysis by phospholipase C is well recognized to form inositol phosphates and diacylglycerol (Berridge 1993) . Thus, we next examined the effect of ␣B-crystallin of the thrombin-induced formation of inositol phosphates. The thrombin-stimulated formation of inositol phosphates was significantly reduced by ␣B-crystallin (Fig 5) . The inhibitory effect on the formation of inositol phosphates was dose dependent in the range between 0.1 and 10 g/mL.
Levels of ␣B-crystallin in plasma of cardiomyopathic hamsters
The Bio 14.6 strain of hamsters shows a predominant hypertrophic stage (Gertz 1992) , and they are most widely used for investigation. Plasma levels of ␣B-crystallin in these cardiomyopathic hamsters were 2.045 ng/mL (n ϭ 3). On the other hand, those in control hamsters were 0.143 ng/ml (n ϭ 3). 
Levels of ␣B-crystallin in hamster injured arteries
The levels of ␣B-crystallin in uninjured artery were 0.57 Ϯ 0.09 g/mg protein. The levels were immediately reduced as compared with those of intact carotid arteries (Fig 6) . The minimum levels of ␣B-crystallin (0.08 Ϯ 0.02 g/mg protein) were observed at 30 minutes after the injury, and the levels were gradually increased.
Immunohistological observation of ␣B-crystallin
Morphological examination was performed in order to further clarify the effect of endothelial injury on the levels of ␣B-crystallin in hamster vessel wall. ␣B-crystallin in uninjured vascular wall was clearly present at high levels (Fig 7a,c) . On the contrary, the levels were markedly reduced by endothelial injury (Fig 7b,d) .
DISCUSSION
HSPs are well recognized to act as molecular chaperones and protect cells from hazardous conditions. However, the details of their physiological roles are not precisely clarified. It has recently been reported that mechanical stretch causes 26% reduction in the levels of ␣B-crystallin, one of low-molecular-weight HSPs, in trabecular meshwork cells within 2 minutes, and the decrease is 90% after 1 hour (Mitton et al 1997) . These findings led us to speculate that some stress might release HSPs such as ␣B-crystallin from cells. In the present study, we investigated the behavior of ␣B-crystallin in detail and its physiological roles in platelet functions.
We showed that the levels of ␣B-crystallin in injured arteries were markedly lower than those of noninjured arteries in vivo. Our findings are consistent with the previous report (Mitton et al 1997) . These results were clearly supported by the data of immunohistochemical observations. Thus, it is probable that ␣B-crystallin is released from vascular wall after endothelial injury. These findings led us to speculate that ␣B-crystallin in normal blood vessel walls immediately responds to mechanical stress, such as endothelial injury in this case, and is probably released from the injured arterial wall into the circulation.
Furthermore, we demonstrated that the ␣B-crystallin levels in plasma of cardiomyopathic hamsters were much higher than those of control hamsters. Thus, this observation strongly suggests that ␣B-crystallin actually functions in pathological conditions.
In the present study, we found that ␣B-crystallin specifically bound to human platelets with the Kd values of 30 nM during the course of investigating the effect of ␣B-crystallin on platelets since platelets are recognized to play crucial roles in thrombus and neointima formation after vascular injury (Ferns et al 1991; Ross 1993) . These findings suggest that platelets have specific binding sites for ␣B-crystallin. Therefore, we suspected that ␣B-crystallin might have important roles in platelets.
In order to investigate the physiological role of the ␣B-crystallin that is released from injured vessel walls, we examined the effect of ␣B-crystallin on the aggregation of platelets in vitro using PRP. We showed that ␣B-crystallin inhibited the aggregation of human platelets induced by botrocetin and thrombin. Botrocetin stimulates platelet aggregation through inducing the binding of von Willebrand factor (vWF) to platelet glycoprotein (GP) 1b (Kawasaki et al 1996) . Thus, our findings suggest that ␣B-crystallin might interact the vWF-GPlb axis. In addition, we demonstrated that thrombin-induced platelet aggregation was significantly suppressed by ␣B-crystallin. We previously showed that Hsp20, a low-molecular-weight HSP, has inhibitory roles in platelet aggregation, but Hsp27 is unable to inhibit (Matsuno et al 1998) . It is recognized that the 3 low-molecular-weight HSPs-␣B-crystallin, Hsp20, and Hsp27-are associated in cells as previously described (Kato et al 1994) . Taking these findings into account, it is possible that when vascular smooth muscle cells are exposed to some stress such as mechanical stress, the 3 HSPs in these cells are dissociated in response to the stress, and then ␣B-crystallin and Hsp20 among them intercellularly modulate platelet functions. In addition, our findings of pharmacokinetics of ␣B-crystallin in hamsters indicate that ␣B-crystallin could play an inhibitory role of platelet activation in vivo after a bolus intravenous injection.
We next examined the effect of ␣B-crystallin on the intracellular signaling system of thrombin in human platelets. ␣B-crystallin significantly suppressed the Ca 2ϩ mobilization and phosphoinositide-hydrolyzing phospholipase C activity induced by thrombin. It is recognized that both intracellular Ca 2ϩ mobilization and the activation of protein kinase C have crucial roles in signal transduction initiated by thrombin receptor activation resulting in regulating platelet functions (Berridge 1993; Grand et al 1996) . Therefore, based on these findings, it is possible that ␣B-crystallin inhibits platelet aggregation through the suppression of these intracellular tranducing events. Further investigations would be necessary to clarify the detailed mechanism of ␣B-crystallin in modulating platelet function.
In conclusion, these results strongly suggest that ␣B-crystallin, which is discharged from vessel walls in response to endothelial injury, acts intercellularly as a regulator of platelet function. Moreover, these findings could be a part of new concept of antiplatelet therapy in the treatment of cardiovascular diseases.
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